Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox
← Back to News

Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion

J

By João L. Carapinha

November 17, 2026

Clinical Practice
three-month dapivirine vaginal ring

The three-month dapivirine vaginal ring has received a positive scientific opinion from the European Medicines Agency (EMA) through its EU-Medicines for All procedure, the Population Council announced on 16 November 2026. The opinion supports use for HIV prevention in women and adolescent girls aged 16 and older, including breastfeeding women.

The ring releases the antiretroviral dapivirine over three months, so users replace it four times per year. The developer expects it to reduce annual product costs by nearly 60% compared with the unsubsidized price of the one-month ring. The one-month ring received a positive EMA scientific opinion in July 2020 and has regulatory approval in 12 African countries.

The opinion follows a Phase I crossover trial of 124 women in South Africa who used both rings. The three-month ring was well tolerated and delivered higher dapivirine levels than the one-month ring, which the release says suggests its efficacy will be at least equal to that of the one-month ring.

Access plans for the three-month dapivirine vaginal ring

To support introduction, the Population Council will transfer the commercial licence for the three-month ring to Kiara Health, a South Africa-based pharmaceutical manufacturer and healthcare solutions provider. Its chief executive, Dr. Skhumbuzo Ngozwana, said the company will work toward introduction in African markets and, over time, explore sustainable local manufacturing. Long-acting HIV prevention is also under way in South Africa, where the lenacapavir PrEP rollout has started.

Why it matters

The cost saving is measured against the unsubsidized price of the one-month ring, so the release gives no absolute price for the three-month ring. The efficacy point rests on drug levels and tolerability in one Phase I crossover study, which the release itself calls suggestive. Syenza News’s CHMP November 2026 roundup reports the same EU-M4All assessment of the dapivirine ring.

Source: Population Council press release, GlobeNewswire, 16 November 2026

Let Google know we are your trusted source.

Add our editorial as a preferred source in your search results.

Trust this Source

Value Science Weekly

The week in health technology assessment, market access and health economics — what moved, and what it means.

You can unsubscribe at any time. Read our privacy policy.

About this newsletter →